Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
L-DOS47 Plus Doxorubicin in Advanced Pancreatic Cancer
NCT04203641Phase 2Terminated
- Sponsor
- Helix BioPharma
- Start
- Dec 2019
- Primary completion
- Oct 2024
- Modality
- Antibody Fragments, Antibody-Drug Conjugates (ADCs), Replacement Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of L-DOS47 in pancreatic cancer (PC), sponsored by Helix BioPharma. Started Dec 2019; status: terminated.
02
Drugs
L-DOS47
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT04203641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04203641.